Neointimal response to second-generation drug-eluting stents in diabetic patients with de-novo coronary lesions. Issue 3 (May 2015)

• Record Type: Journal Article
• Authors: Won, Hoyoun; Kang, Tae Soo; Hong, Bum-Kee; Lee, Seunghwan; Jeon, Dong Woon; Ryu, Sung Kee; Min, Pil-Ki; Yoon, Young Won; Lee, Byoung Kwon; Kwon, Hyuck Moon; Ko, Young-Guk; Jang, Yangsoo
• Is Part Of: Coronary artery disease. Volume 26:Issue 3(2015:May)
• Publication Date: 2015-05
• Subjects: Coronary heart disease -- Periodicals; Coronary Disease -- Indexes; Coronary Disease -- Periodicals; 616.123005
• DOI: 10.1097/MCA.0000000000000195
• Languages: English
• ISSNs: 0954-6928

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>Objectives</title> <p>The aim of this study was to evaluate the extent of neointimal response after the implantation of a second-generation drug-eluting stent, zotarolimus-eluting stent (ZES-ER, Endeavor Resolute) or everolimus-eluting stent (EES, Xience V), using intravascular ultrasound (IVUS) in diabetic patients.</p> </sec> <sec> <title>Materials and methods</title> <p>In all, 154 diabetic patients with de-novo coronary lesions were randomized to be implanted with a ZES-ER or EES, and the angiographic follow-up at 9 months combined with a complete IVUS study was available for 96 patients with 101 lesions.</p> </sec> <sec> <title>Results</title> <p>Baseline demographic and lesion parameters were similar in both groups at index percutaneous coronary intervention. On follow-up angiography, in-stent late lumen loss and minimal lumen diameter were not different between the two groups. On IVUS study, neointimal hyperplasia volume [median (interquartile range): ZES-ER vs. EES; 2.25 mm<sup>3</sup> (0.57–6.25) vs. 1.59 mm<sup>3</sup> (0.45–8.37), <italic>P</italic>=0.615] and in-stent percentage of volume obstruction [median (interquartile range): ZES-ER vs. EES; 1.16% (0.33–3.61) vs. 0.77% (0.29–4.01), <italic>P</italic>=0.615] showed similar results between the two groups.</p> </sec> <sec> <title>Conclusion</title> <p>In diabetic patients, the second-generation drug-eluting stents, ZES-ER and EES, were comparable in inhibiting neointimal proliferation.</p> </sec> </abstract>